CD19 and lymphoma: Allo-CARs sourced from healthy donors for patients with r/r lymphomas include ALLO-501, a genetically modified anti-CD19 CAR T cell product where the TCR alpha gene is disrupted to reduce the risk of GvHD, and the CD52 gene is disrupted to permit the use of an anti-CD52 monoclonal antibody (mAb), ALLO-647, for selective and prolonged host lymphodepletion.